Cardiol Therapeutics Inc. (NASDAQ:CRDL – Free Report) – Roth Capital issued their Q2 2024 EPS estimates for Cardiol Therapeutics in a note issued to investors on Wednesday, June 26th. Roth Capital analyst J. Wittes anticipates that the company will post earnings of ($0.09) per share for the quarter. Roth Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.34) per share. Roth Capital also issued estimates for Cardiol Therapeutics’ Q3 2024 earnings at ($0.09) EPS, Q4 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.37) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.35) EPS, Q1 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.39) EPS.
Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.04).
Get Our Latest Report on Cardiol Therapeutics
Cardiol Therapeutics Price Performance
Shares of CRDL opened at $2.02 on Friday. The firm has a market capitalization of $139.38 million, a PE ratio of -5.77 and a beta of 0.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.81 and a quick ratio of 2.81. Cardiol Therapeutics has a 1-year low of $0.66 and a 1-year high of $3.12. The company’s fifty day moving average price is $2.21 and its 200-day moving average price is $1.65.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Cardiol Therapeutics stock. Tejara Capital Ltd grew its position in Cardiol Therapeutics Inc. (NASDAQ:CRDL – Free Report) by 29.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 645,457 shares of the company’s stock after acquiring an additional 148,396 shares during the period. Tejara Capital Ltd owned about 1.00% of Cardiol Therapeutics worth $578,000 at the end of the most recent quarter. 12.49% of the stock is currently owned by hedge funds and other institutional investors.
Cardiol Therapeutics Company Profile
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Read More
- Five stocks we like better than Cardiol Therapeutics
- Insider Trades May Not Tell You What You Think
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- The 3 Best Blue-Chip Stocks to Buy Now
- MarketBeat Week in Review – 6/24 – 6/28
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.